Zepbound Lawsuit: NAION Vision-Loss Claims and What Zepbound Does Not Cover

Marin & MurphySuper Lawyers® 2014–2024(888) 348-2735

Ozempic (GLP-1) Lawsuit — Free Case Review

Which Medications — and Which Injuries — Qualify

Eligibility differs by drug and by injury track. Check yours against the current criteria in minutes.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.

Did this happen to you — or someone you love?

Start your free case reviewTell us anyway

Answered 24/7 · Free & confidential · No fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney's fee is a percentage of the gross recovery, calculated before expenses are deducted.

(888) 348-2735

Partners

Matthew T. Marin & Stefanie A. Murphy

Super Lawyers® honorees · American Association for Justice members

Ozempic inquiries get a personal review — and an honest answer either way, free and without obligation.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Attorney Advertising.

Zepbound is Eli Lilly’s tirzepatide product for weight management, and under the current GLP-1 referral criteria it qualifies for the NAION sudden vision-loss track only — the stomach-injury track is limited to brand-name semaglutide (Ozempic, Wegovy, Rybelsus). Marin & Murphy is currently accepting Ozempic (GLP-1) NAION cases.

One track, not two — here is the line

The GLP-1 litigation splits into two separate federal proceedings with two different injuries and two different medication lists. For Zepbound, the split matters immediately:

• NAION vision-loss track — Zepbound qualifies. The referral criteria cover brand-name Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound. What is required is an actual NAION diagnosis and some degree of permanent vision impairment, diagnosed while taking the medication or after stopping.
• Stomach-injury track — Zepbound does not currently qualify. Gastroparesis and gastric-obstruction claims under these criteria require brand-name semaglutide. Zepbound, Mounjaro, and Trulicity do not meet them.

Zepbound also sits in an unusual place in the court records, worth stating precisely. The Eastern District of Pennsylvania’s published product list for the stomach-injury MDL names five products — Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro — and does not name Zepbound. New Jersey’s state-court designation is broader and does name it among the six medications covered. Whether Zepbound falls within the federal stomach MDL’s product scope is genuinely unsettled on the public record — another reason a Zepbound stomach-injury inquiry deserves review rather than a form answer.

Where Zepbound NAION cases go

Federal NAION claims are consolidated in MDL 3163, In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, in the Eastern District of Pennsylvania before Judge Karen S. Marston — created December 15, 2025 with 20 centralized actions, and holding 216 pending actions as of the JPML’s September 1, 2026 report.

The consolidation ran opposite to the usual pattern. Eli Lilly — a defendant — filed the motion to transfer on August 19, 2025 covering 21 actions. Plaintiffs opposed centralization; Novo Nordisk supported it. The Panel granted it, finding common questions about the development, testing, regulatory history, promotion, and labeling of these products and their capacity to cause NAION, and kept it separate from the older stomach-injury MDL so the judge could set the level of coordination.

New Jersey designated two separate GLP-1 multicounty litigations by Supreme Court order of October 16, 2025 — gastrointestinal and NAION — both in Bergen County before Judge Gregg A. Padovano, with Zepbound expressly named.

What NAION is, in plain terms

Non-arteritic anterior ischemic optic neuropathy is a loss of blood flow to the front of the optic nerve. It comes on suddenly, usually in one eye, usually without pain, often overnight — people describe waking up and finding part of their field of vision gone, frequently the lower half. Average onset age is in the mid-sixties, no treatment has been shown to reverse it, and most patients remain stable rather than improve.

What matters for a claim is the diagnosis itself. Many people are told there is no known cause; that is the standard clinical answer and it is not a bar. The criteria require that an actual NAION diagnosis exists in the records — typically from an ophthalmologist or neuro-ophthalmologist, usually with giant-cell arteritis ruled out — and that some permanent vision impairment remains.

FDA adverse-event data for tirzepatide

As of the July 30, 2026 data refresh, FDA’s FAERS database held 160,663 total reports and 28,502 serious reports for tirzepatide, the active ingredient in Zepbound and Mounjaro, including 1,151 reports coded as visual impairment and 878 as blurred vision. Reports submitted to FDA are not verified and do not establish causation — they are voluntary, unvalidated submissions that can be duplicated and that rise with prescribing volume and news coverage.

Stated candidly: the FAERS term used for NAION does not appear among tirzepatide’s top 200 reported reactions, while it appears 631 times for semaglutide. The published research on this signal has focused on semaglutide, including the July 3, 2024 JAMA Ophthalmology cohort study and the European Medicines Agency’s June 6, 2025 conclusion that NAION is a very rare side effect of semaglutide medicines. Raw report counts cannot establish relative risk between drugs, and the NAION referral criteria include Zepbound because the individual diagnosis governs, not the database.

Who may qualify

• NAION — the Zepbound track: use of brand-name Zepbound (or Mounjaro, Trulicity, Ozempic, Wegovy, Rybelsus); an actual NAION diagnosis made while taking the medication or after stopping; and some degree of permanent vision impairment. No age gate, no diagnosis-date cutoff, and no hospitalization requirement apply to this track.
• Useful to have on hand: the diagnosing eye doctor’s practice name, the date vision changed, which eye, your last dose date, and whether giant-cell arteritis was ruled out. You do not need any of it to start a conversation.
• Stomach injuries: not covered by the current criteria for Zepbound. If you were hospitalized with a documented stomach injury while taking Zepbound, tell us anyway — that is a review path, not a closed door.
• Compounded tirzepatide from a med spa or telehealth service does not meet the brand-name requirement. Pharmacy records, invoices, and vial or pen labels usually settle which one you had.
• Not your doctor. The claim is against Eli Lilly, the manufacturer. Not your prescriber, not your pharmacy.

If you are reading this for a spouse or a parent

You are in the right place, and you do not need their permission to ask questions. A person who lost vision in one eye a few weeks ago is often not the one doing the research — the reading, the calling, and the piecing-together usually fall to someone else in the household. Nothing about a case review requires the patient to make a decision today.

The honest posture

The NAION proceeding is eight months old and moving quickly in filings but not in outcomes. On July 2, 2026 the court granted early motion practice on general causation and preemption and directed the parties to exchange fact sheets and records proving use and diagnosis; on July 21, 2026 it appointed a special discovery master. There is no expert schedule, no bellwether pool, and no trial date in MDL 3163. In the older stomach-injury MDL, a Rule 702 hearing runs September 14 through 18, 2026. No court has ruled on whether these medications cause NAION.

Common questions

Other GLP-1 medications: Wegovy, Rybelsus, Mounjaro, Trulicity, and compounded semaglutide. The manufacturer: Eli Lilly.